Revance(RVNC) Prnewswire·2025-02-14 10:45Core Viewpoint - Revance Therapeutics, Inc. is facing a class action securities lawsuit due to alleged securities fraud that occurred between February 29, 2024, and December 6, 2024 [1][2] Group 1: Allegations and Impact - The lawsuit claims that Revance was in material breach of its Distribution Agreement with Teoxane, which granted it exclusive rights to market and distribute Teoxane's dermal fillers [2] - This breach allegedly increased the risk of litigation and caused monetary and reputational harm to the company [2] - The situation heightened the risk of delays or amendments to a tender offer, leading to materially false and misleading public statements by the company [2] Group 2: Legal Process and Participation - Investors who suffered losses during the specified timeframe have until March 4, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this role [3] - Class members may be entitled to compensation without incurring any out-of-pocket costs or fees [3] Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [4] - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the U.S. [4]